Targeting the Suprachoroidal Space in Treating Noninfectious Uveitic Macular Edema (Online CME Monograph)
Activity Description and Purpose
The suprachoroidal space is a new and attractive option for medication delivery that allows for targeted release of steroids that can treat macular edema with minimal side effects. Experts will provide information on uveitic macular edema that encompasses the epidemiology, pathophysiology, impact on vision loss, diagnostic criteria, relevant injection techniques, and efficacy and safety of current and emerging treatments. The desired results of this activity are for retina specialists and other ophthalmologists to enhance their awareness and understanding of the suprachoroidal space as a target for medication delivery in noninfectious uveitic macular edema.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Review diagnostic criteria for noninfectious uveitic macular edema
- Describe the role of the suprachoroidal space as a delivery target in the treatment of uveitic macular edema
- Discuss the clinically relevant data of triamcinolone acetonide for the treatment of uveitic macular edema
- Apply the appropriate injection technique to deliver triamcinolone acetonide into the suprachoroidal space for the treatment of uveitic macular edema
- Use evidence-based approaches for local treatment of macular edema associated with uveitis
Steven Yeh, MD (Chair)
|Parisa Emami-Naeini, MD, MPH|
Director, Uveitis and Ocular Inflammation Service
University of California, Davis
|Jessica Shantha, MD|
University of California, San Francisco
San Francisco, California
|Nathan C. Steinle, MD|
California Retina Consultants
Santa Barbara, California
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Parisa Emami-Naeini, MD, MPH, has no relevant commercial relationships to disclose.
Jessica Shantha, MD, has no relevant commercial relationships to disclose.
Nathan C. Steinle, MD, is a consultant for Allergan, Bausch & Lomb Incorporated, Genentech, Inc, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Regenxbio Inc.
Steven Yeh, MD, is a consultant for Adverum, Alcon, Allergan, Bausch & Lomb Incorporated, Clearside Biomedical, Inc, and Regenxbio Inc.
Danny Mammo, MD, formerly served as an advisory board member for Alimera Sciences, EyePoint Pharmaceuticals, and Genentech, Inc, within the past 2 years, but those relationships have ended.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Tony Realini, MD, MPH, is a consultant for Belkin Laser, New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma Inc, and Sight Sciences; and was previously a consultant for iStar Medical and Ivantis Inc within the past 2 years, but those relationships have ended.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Bausch & Lomb Incorporated, or Retina.
©2022 MedEdicus LLC. 271
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation